Evidence map›Paper›PMID 24651852›Full record

ArticlePloS one2014

Defects in the C. elegans acyl-CoA synthase, acs-3, and nuclear hormone receptor, nhr-25, cause sensitivity to distinct, but overlapping stresses.

Jordan D Ward, Brendan Mullaney, Benjamin J Schiller, Le D He, Sarah E Petnic, Carole Couillault, Nathalie Pujol, Teresita U Bernal, Marc R Van Gilst, Kaveh Ashrafi and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. The Binding Landscape of an Essential Nuclear Hormone Receptor inbioRxiv : the preprint server for biology · 2025
    Article
  3. MLT-11 is necessary forbioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. The NHR-23-regulated putative protease inhibitorbioRxiv : the preprint server for biology · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Mitochondrial NaFrontiers in pharmacology · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jordan D WardDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, United States of America.
Brendan MullaneyDepartment of Physiology, University of California San Francisco, San Francisco, California, United States of America.
Benjamin J SchillerDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, United States of America.
Le D HeCentre d'Immunologie de Marseille-Luminy (CIML), UM2 Aix-Marseille Université, Marseille, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.
Sarah E PetnicDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, United States of America.
Carole CouillaultCentre d'Immunologie de Marseille-Luminy (CIML), UM2 Aix-Marseille Université, Marseille, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.
Nathalie PujolCentre d'Immunologie de Marseille-Luminy (CIML), UM2 Aix-Marseille Université, Marseille, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.
Teresita U BernalDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, United States of America.
Marc R Van GilstDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Kaveh AshrafiDepartment of Physiology, University of California San Francisco, San Francisco, California, United States of America.
Jonathan J EwbankCentre d'Immunologie de Marseille-Luminy (CIML), UM2 Aix-Marseille Université, Marseille, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.
Keith R YamamotoDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, United States of America.
University of California, San Francisco · USInserm · FRCentre National de la Recherche Scientifique · FRFred Hutch Cancer Center · US

Funding

GENE REGULATION BY STEROID RECEPTOR PROTEINSR01CA020535 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YAMAMOTO, KEITH ROBERT · 1985 to 2018
$8.9M
Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
A platform for rapid characterization of metabolic disrupters in whole animalsR21ES021412 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ASHRAFI, KAVEH, BAINTON, ROLAND J · 2012 to 2013
$420k
GENE REGULATION BY STEROID RECEPTOR PROTEINSR37CA020535 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI YAMAMOTO, KEITH ROBERT · 1990 to 1998
–
CIHR 234765NCI NIH HHS CA20535NCI NIH HHS R01 CA020535NCI NIH HHS R37 CA020535NIEHS NIH HHS ES021412-01NIEHS NIH HHS R21 ES021412NIH HHS P40 OD010440PHS HHS MCB-1157767
6 · The paper itself

Abstract

Metazoan transcription factors control distinct networks of genes in specific tissues, yet understanding how these networks are integrated into physiology, development, and homeostasis remains challenging. Inactivation of the nuclear hormone receptor nhr-25 ameliorates developmental and metabolic phenotypes associated with loss of function of an acyl-CoA synthetase gene, acs-3. ACS-3 activity prevents aberrantly high NHR-25 activity. Here, we investigated this relationship further by examining gene expression patterns following acs-3 and nhr-25 inactivation. Unexpectedly, we found that the acs-3 mutation or nhr-25 RNAi resulted in similar transcriptomes with enrichment in innate immunity and stress response gene expression. Mutants of either gene exhibited distinct sensitivities to pathogens and environmental stresses. Only nhr-25 was required for wild-type levels of resistance to the bacterial pathogen P. aeruginosa and only acs-3 was required for wild-type levels of resistance to osmotic stress and the oxidative stress generator, juglone. Inactivation of either acs-3 or nhr-25 compromised lifespan and resistance to the fungal pathogen D. coniospora. Double mutants exhibited more severe defects in the lifespan and P. aeruginosa assays, but were similar to the single mutants in other assays. Finally, acs-3 mutants displayed defects in their epidermal surface barrier, potentially accounting for the observed sensitivities. Together, these data indicate that inactivation of either acs-3 or nhr-25 causes stress sensitivity and increased expression of innate immunity/stress genes, most likely by different mechanisms. Elevated expression of these immune/stress genes appears to abrogate the transcriptional signatures relevant to metabolism and development.

Indexed as

Stress, PhysiologicalAnimalsAnimals, Genetically ModifiedAntimicrobial Cationic PeptidesCaenorhabditis elegansCoenzyme A LigasesDNA-Binding ProteinsGene Expression RegulationGene Knockout TechniquesGenetic Association StudiesLong-Chain-Fatty-Acid-CoA LigaseLongevityMutationPhenotypeRNA InterferenceTranscription FactorsAntimicrobial Cationic PeptidesCoenzyme A LigasesDNA-Binding ProteinsLong-Chain-Fatty-Acid-CoA Ligasenuclear hormone receptor NHR-25, C elegansTranscription Factors

Identifiers

PMID24651852
PMCPMC3961378
OpenAlexW2057661816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.